Rathbones Group PLC Has $13.31 Million Stock Position in AbbVie Inc. $ABBV

Rathbones Group PLC lessened its position in shares of AbbVie Inc. (NYSE:ABBV) by 2.9% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 71,713 shares of the company’s stock after selling 2,143 shares during the quarter. Rathbones Group PLC’s holdings in AbbVie were worth $13,311,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in ABBV. Conning Inc. raised its holdings in AbbVie by 7.1% in the 2nd quarter. Conning Inc. now owns 191,023 shares of the company’s stock valued at $35,458,000 after acquiring an additional 12,690 shares during the period. Dohj LLC grew its position in shares of AbbVie by 41.8% in the second quarter. Dohj LLC now owns 4,529 shares of the company’s stock valued at $802,000 after purchasing an additional 1,335 shares during the last quarter. First Hawaiian Bank increased its stake in shares of AbbVie by 0.8% during the second quarter. First Hawaiian Bank now owns 7,556 shares of the company’s stock worth $1,403,000 after purchasing an additional 60 shares during the period. BankPlus Trust Department lifted its holdings in AbbVie by 3.3% during the 2nd quarter. BankPlus Trust Department now owns 27,113 shares of the company’s stock worth $5,033,000 after purchasing an additional 855 shares during the last quarter. Finally, North Star Asset Management Inc. boosted its stake in AbbVie by 0.5% in the 1st quarter. North Star Asset Management Inc. now owns 161,320 shares of the company’s stock valued at $33,800,000 after purchasing an additional 756 shares during the period. 70.23% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

ABBV has been the topic of several recent research reports. Citigroup lowered their price objective on AbbVie from $240.00 to $235.00 and set a “neutral” rating on the stock in a research report on Monday, November 3rd. UBS Group upped their price target on shares of AbbVie from $195.00 to $220.00 and gave the company a “neutral” rating in a research note on Friday. HSBC set a $225.00 price objective on shares of AbbVie in a research note on Thursday, October 2nd. Raymond James Financial set a $256.00 target price on shares of AbbVie in a research report on Monday, November 3rd. Finally, Hsbc Global Res downgraded shares of AbbVie from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 1st. Two analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and ten have assigned a Hold rating to the company. According to MarketBeat, AbbVie has a consensus rating of “Moderate Buy” and a consensus price target of $236.57.

AbbVie Price Performance

Shares of NYSE:ABBV opened at $218.92 on Monday. The firm has a 50 day moving average of $223.24 and a 200-day moving average of $202.67. The stock has a market capitalization of $386.92 billion, a PE ratio of 104.25, a PEG ratio of 1.42 and a beta of 0.50. The company has a current ratio of 0.74, a quick ratio of 0.61 and a debt-to-equity ratio of 44.14. AbbVie Inc. has a 12 month low of $163.81 and a 12 month high of $244.81.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.77 by $0.09. AbbVie had a net margin of 6.45% and a return on equity of 699.66%. The business had revenue of $15.78 billion for the quarter, compared to analyst estimates of $15.58 billion. During the same quarter last year, the business posted $3.00 EPS. The firm’s revenue for the quarter was up 9.1% on a year-over-year basis. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. On average, equities research analysts predict that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be given a dividend of $1.73 per share. The ex-dividend date is Friday, January 16th. This represents a $6.92 annualized dividend and a dividend yield of 3.2%. This is an increase from AbbVie’s previous quarterly dividend of $1.64. AbbVie’s dividend payout ratio is currently 524.24%.

Insider Buying and Selling at AbbVie

In related news, EVP Azita Saleki-Gerhardt sold 42,370 shares of the firm’s stock in a transaction dated Tuesday, August 12th. The stock was sold at an average price of $198.42, for a total value of $8,407,055.40. Following the sale, the executive vice president directly owned 177,292 shares of the company’s stock, valued at $35,178,278.64. This trade represents a 19.29% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. 0.25% of the stock is currently owned by corporate insiders.

AbbVie Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.